Document Detail

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
MedLine Citation:
PMID:  20605207     Owner:  NLM     Status:  MEDLINE    
This phase I/II study was designed to demonstrate the tolerance and the efficacy of a combination of pegylated interferon-α 2a to Imatinib mesylate (IM) 600mg daily in cytogenetically IM-resistant but in CHR chronic phase CML patients. The combination was generally well tolerated in the 15 evaluable patients. A significant reduction of the Ph1(+) BM metaphases was observed in these poor prognosis patients, with 2 long-term CCyR including 2 MMR. After a median follow-up of 43 months, 93% of patients are alive. The addition of PegIFNα2a to IM600 is feasible, and able to overcome resistance within this context.
Franck E Nicolini; Sandrine Hayette; Laurence Legros; Philippe Rousselot; Frédéric Maloisel; Michel Tulliez; Agnès Guerci; Aude Charbonnier; Thomas Prébet; Françoise Rigal-Huguet; Kaddour Chabane; Jean-Pierre Magaud; Carole Paillet; Christine Pivot; Mauricette Michallet
Related Documents :
18488157 - Thirty patients with primary plasma cell leukemia: a single center experience.
7967757 - Efficacy of fluorescence in situ hybridization for detecting pml/rara gene fusion in tr...
3886417 - Cyclosporin a in marrow transplantation for leukemia and aplastic anemia.
1521237 - Cell-cycle progression rates and sister chromatid exchange frequencies in the bone marr...
18757147 - Factors predictive of complicated or severe alcohol withdrawal in alcohol dependent inp...
12169907 - Laryngeal electromyography in the management of vocal cord mobility problems in children.
Publication Detail:
Type:  Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study     Date:  2010-06-03
Journal Detail:
Title:  Leukemia research     Volume:  35     ISSN:  1873-5835     ISO Abbreviation:  Leuk. Res.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-20     Completed Date:  2011-01-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  80-6     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier Ltd. All rights reserved.
Département d'hématologie clinique, hôpital Edouard Herriot, Lyon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage*,  adverse effects,  therapeutic use
Interferon Alfa-2a / administration & dosage*,  adverse effects,  therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*,  genetics,  pathology
Middle Aged
Piperazines / administration & dosage*,  adverse effects,  therapeutic use
Polyethylene Glycols / administration & dosage*,  adverse effects,  therapeutic use
Pyrimidines / administration & dosage*,  adverse effects,  therapeutic use
Remission Induction*
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Polyethylene Glycols; 0/Pyrimidines; 0/peginterferon alfa-2a; 152459-95-5/imatinib; 76543-88-9/Interferon Alfa-2a

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The down regulation of target genes by photo activated DNA nanoscissors.
Next Document:  ABVD associated with imatinib for coexisting chronic myeloid leukaemia and relapsed Hodgkin lymphoma...